Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Group LLC in a note issued to investors on Friday, October 6th. They currently have a $15.00 price objective on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 33.33% from the company’s current price.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. ValuEngine raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a report on Friday, June 9th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Finally, HC Wainwright started coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $20.00.
Collegium Pharmaceutical (NASDAQ:COLL) opened at 11.24 on Friday. The company’s 50-day moving average is $10.76 and its 200 day moving average is $10.76. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $18.67. The company’s market capitalization is $332.32 million.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $4.07 million. On average, analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://baseballnewssource.com/markets/jefferies-group-llc-reiterates-buy-rating-for-collegium-pharmaceutical-inc-coll/1698319.html.
Several institutional investors and hedge funds have recently modified their holdings of COLL. American International Group Inc. increased its position in shares of Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Collegium Pharmaceutical by 16.4% during the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares in the last quarter. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical in the 2nd quarter valued at $125,000. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% in the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares in the last quarter. Hedge funds and other institutional investors own 83.04% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.